Clinical Trials Logo

Polycythemia clinical trials

View clinical trials related to Polycythemia.

Filter by:

NCT ID: NCT00726232 Terminated - Clinical trials for Myeloproliferative Neoplasm (MPN)

Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia

Start date: August 20, 2008
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy profile of different treatment regimens of Ruxolitinib (INCB018424) administered to two groups of patients; those with polycythemia vera (PV) and those with essential thrombocythemia (ET). Patients in each group were refractory to hydroxyurea or for whom hydroxyurea is contraindicated.

NCT ID: NCT00595829 Terminated - Polycythemia Vera Clinical Trials

A Phase 1 Study of XL019 in Adults With Polycythemia Vera

Start date: December 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of the JAK2 inhibitor XL019 administered orally in adults with Polycythemia Vera.

NCT ID: NCT00522574 Terminated - Myelofibrosis Clinical Trials

A Safety Study of XL019 in Adults With Myelofibrosis

Start date: August 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of XL019 in adults with myelofibrosis. XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. JAK2 is activated by cytokine and growth factor receptors and phosphorylates members of the STAT family of inducible transcription factors. Activation of the JAK/STAT pathway promotes cell growth and survival, and is a common feature of human tumors. JAK2 is activated by mutation in the majority of patients with myelofibrosis, polycythemia vera and essential thrombocytosis and appears to drive the inappropriate growth of blood cells in these conditions.